

PharmaTech
Integrates

NEWSLETTER

October 2021

Life Science Integrates, in partnership with the Medicines Manufacturing Innovation Centre, deliver a successful inaugural conference driving momentum and collaboration in PharmaTech

We are delighted by the success of our very first PharmaTech Integrates event on 23 September. Following in the footsteps of our well-established MedTech Integrates, Pharma Integrates and Bio Integrates conferences, this inaugural event served as a forum to share, discuss, debate and challenge the position of technology in the UK today. With over 80 speakers, 19 sponsors, and 500 attendees, the event provided unique opportunities for the sharing of ideas between leaders and innovators via panel discussions, showcases, interviews, and networking.

Dave Tudor, Managing Director of the Medicines Manufacturing Innovation Centre (MMIC) - our event partners - opened the



conference, highlighting three integral considerations for moving this sector forward: achieving a balanced view of technology, strategizing technol-

ogy, and building networks to accelerate progress. With contributions from the fields of synthetic chemistry, biologics, digital technology and more, PharmaTech Integrates reflected that balanced view

and Dave concluded with two words that captured major themes of the event: momentum and collaboration... *To read more:* <https://www.lifescienceintegrates.com/life-science-integrates-in-partnership-with-the-medicines-manufacturing-innovation-centre-deliver-a-successful-inaugural-conference-driving-momentum-and-collaboration-in-pharmatech/>




Dave Tudor, Managing Director of the Medicines Manufacturing Innovation Centre (MMIC)



UK Research
and Innovation



Scottish Government
Riaghaltas na h-Alba
gov.scot



October 2021

Interviews



Using data-driven approached to enable demand-led pharmaceutical supply

Dave Tudor, Managing Director, CPI

<https://sstv.it/wfPUFd>

Digital Twins and MicroFactories

Prof Alastair Florence Director at CMAC

<https://sstv.it/Rd8Drt>

Intense thinking for API manufacture


Dr. Rajeev Rehani Budhdev, Executive Vice President and Head - Dr. Reddy's

<https://sstv.it/EZxVLg>

Revolution not evolution of Biologics production

Mark Proctor CBE, General Manager R&D Operations - AstraZeneca

<https://sstv.it/a3yHoA>



Unravelling threads and finding patterns in data to understand quality deviations

Danny Reeves, CEO - Exonar

<https://sstv.it/f03jXO>

Revolution not evolution of Biologics production

Jamie Unwin,

Commercial Insights Officer, Nanoform


<https://sstv.it/cNsJp0>

Supply Chain - Pain Relief

John Arthur,

Director, Medicines Manufacturing Innovation Centre

<https://sstv.it/nd9v82>





NEWSLETTER

October 2021 Articles

SK pharmteco: a unified approach to supporting pharma and biotech manufacturing

In an exclusive interview for Life Science Integrates, Aslam Malik, CEO, explains how SK pharmteco has become established as a single customer-facing team offering a synergistic combination of complementary manufacturing services to support pharmaceutical and biotech product manufacture.

LSI: How and why was SK pharmteco established in its present form and what specifically is its mission?

To read more: <https://www.lskh.digital/article/sk-pharmteco-a-unified-approach-to-supporting-pharma-and-biotech-manufacturing/>

Open Innovation: Redefining the future lab

Dr Kath Mackay, Director of Life Sciences, Bruntwood SciTech – Alderley Park explores why the time is now for science and what this means for the future of the lab.

The past year has proven to be a catalyst for global business change and never has the life sciences sector been more in the spotlight. From testing and drug discovery to the roll out of the vaccine, collaboration and open innovation have been vital in accelerating scientific progress and will be central to the future of the laboratory

To read more: <https://www.lskh.digital/article/open-innovation-redefining-the-future-lab/>

October 2021 News

Optibrium releases 3D ligand-based design module for drug discovery software

Drug discovery software developer Optibrium Ltd has released the latest version of StarDrop, its comprehensive software platform for small-molecule design, optimization and data analysis. StarDrop 7.1 further expands the platform's 3D ligand-based design capabilities, providing access to high-performance methods for virtual screening and intuitive compound design in discovery projects where little or... To read more: <https://www.lskh.digital/news/optibrium-releases-3d-ligand-based-design-module-for-drug-discovery-software/>

BIOVECTRA enhances manufacturing capacity with ABEC microbial fermentation technology

ABEC, a global provider of integrated solutions and services for biopharmaceutical manufacturing, is to design, manufacture, and install CSR single-use microbial fermentation solutions at BIOVECTRA's manufacturing facility in Windsor, Nova Scotia, Canada to enhance BIOVECTRA's high-growth microbial fermentation processes... To read more: <https://www.lskh.digital/news/biovectra-enhances-manufacturing-capacity-with-abec-microbial-fermentation-technology/>

GammaDelta Therapeutics initiates Phase 1 trial of AML treatment

GammaDelta Therapeutics Ltd, a biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for cancer, has initiated a first-in-human Phase 1 clinical trial evaluating GDX012 for the treatment of acute myeloid leukaemia (AML). GDX012 is an allogeneic, non-engineered, variable delta 1 gamma-delta T cell therapy manufactured from healthy donor blood. AML is



Dr Paolo Paoletti, CEO of GDT

the most common form of acute leukaemia in adults with an estimated 20,000 new cases per year in the US. Despite progress in the development of targeted therapies over recent years, the prognosis for patients with AML remains poor, with an average overall five-year survival rate of approximately 30%... **To read more:** <https://www.lskh.digital/news/gamma-delta-therapeutics-initiates-phase-1-trial-of-aml-treatment/>

Cellbox Solutions establishes US subsidiary

Cellbox Solutions GmbH has established a US subsidiary which is now selling products directly to the North American market. The company decided to expand to the USA following the successful development and production of the Cellbox transportable CO₂ incubator, as well as of suitable UN3373 packaging materials for cell transport, and the high amount of enquiries from the US market for these products. The market was previously.. **To read more:** <https://www.lskh.digital/news/cell-box-solutions-establishes-us-subsiary/>

Boehringer Ingelheim acquires Abexxa Biologics

Boehringer Ingelheim has acquired Abexxa Biologics Inc., a biopharmaceutical company specializing in immuno-oncology and oncology research, giving it access to Abexxa's expertise in targeting cancer-specific proteins that are located inside the cell, rather than those expressed on the cell membrane, thus enlarging the pool of potential cancer antigen targets and potentially leading to the development of cancer immunotherapies that are effective in a broader range of patients and cancer types.

"The acquisition of Abexxa bolsters our commitment to tumour-antigen discovery and new ways of targeting.. **To read more:** <https://www.lskh.digital/news/boehringer-ingelheim-acquires-abexxa-biologics/>

NEWSLETTER

October 2021 News

Metrion Biosciences expands into new headquarters at Granta Park

Ion channel contract research and drug discovery company Metrion Biosciences has moved to larger, custom-designed laboratory and office premises at Granta Park, Cambridge, UK which, the company says will allow it to significantly expand its range of services and cell lines. The 12,000 sq. ft (1,145 sq m) facility more than doubles Metrion Biosciences' laboratory space and has been specifically designed to support the addition of GLP-compliant cardiac safety services and expanded cell biology facilities. The new laboratories



provide significant additional capacity for ongoing and future client projects, and dedicated laboratory space for the introduction of 384-well format automated electrophysiology and enhanced liquid handling... *To read more:* <https://www.lskh.digital/news/metrion-biosciences-expands-into-new-headquarters-at-granta-park/>



Dr Andrew Southan

Owlstone Medical closes \$58 million financing round

Owlstone Medical, the developer of Breath Biopsy for applications in early disease detection and precision medicine, has closed a Series D financing round that significantly exceeded its \$50 million target, securing \$58 million in funding (c. £42 million), bringing the total raised by the company to over \$150 million (c. £109 million) since its founding in 2016. The round was led by returning investor Horizons Ventures... *To read more:* <https://www.lskh.digital/news/owlstone-medical-closes-58-million-financing-round/>

AstraZeneca to invest \$360 million in advanced manufacturing facility in Ireland

AstraZeneca is planning on establishing a next-generation active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin, Ireland which will allow for late-stage development and early commercial supply through the application of state-of-the-art process technology and digital innovation. *To read more:* <https://www.lskh.digital/news/astrazeneca-to-invest-360-million-in-advanced-manufacturing-facility-in-ireland/>



The must attend event for senior leaders of pharma and healthcare

This one-day, live streamed conference is centred around three streams of debate-led panel discussion. Focussing on this year's themes of People, Processes and Predictions, Pharma Integrates 2021 attracts speakers from across the world, with participation from leading pharmaceutical companies, disruptive entrants and start-ups, regulators and academics.

With live Q&A available throughout, Pharma Integrates 2021 will explore current challenges and opportunities in the sector, and encourage collaborative relationships that will transform the future of patient care; these conversations will continue to shape the industry today and for the future.

This headline event for Life Science Integrates attracts over 100 speakers and 500 senior executive attendees from:

- Small to large pharma companies
- Biotechs
- Supply chain and technology providers
- Regulatory bodies
- Government Agencies
- CDMOs and CROs
- Consultants
- Patient groups
- Medical research charities
- Academics

To celebrate the 10th Edition of Pharma Integrates on 16 November 2021 we have 50 complimentary tickets available, register go to this link:
REGISTER TODAY USING COUPON PI-100